uploads/2017/12/Velcade.png

How Did JNJ’s Velcade and Procrit Perform in 3Q17?

By

Updated

Velcade revenue trends

In 3Q17, Johnson & Johnson’s (JNJ) Velcade generated revenues of $273 million, a ~10% decline on a year-over-year (or YoY) basis and a 6% decline quarter-over-quarter. Velcade reported YTD September 2017 revenues of $843 million compared to $950 million in YTD September 2016.

Velcade (bortezomib) is used for the treatment of individuals with multiple myeloma and mantle cell lymphoma. Velcade’s peers in the multiple myeloma drugs market include Amgen’s (AMGN) Kyprolis and Takeda Pharmaceuticals (TKPYY) Ninlaro. In 3Q17, Kyprolis reported revenues of $207 million.

Article continues below advertisement

Procrit revenue trends

In 3Q17, Procrit generated revenues of $238 million, which reflected a ~5% decline on a YoY basis and a 7% decline on a quarter-over-quarter basis. In 3Q17, in the US market and outside the US market, Procrit generated revenues of $168 million and $70 million, respectively. Procrit’s year-over-year revenues remained flat in the US market.

Procrit reported YTD September 2017 revenues of $740 million compared to $846 million in YTD September 2016.

Procrit is used for the treatment of individuals with anemia due to chronic kidney disease. Procrit is also used for decreasing allogenic RBC transfusion in individuals undergoing elective noncardiac, nonvascular surgery.

Procrit’s competitors include Amgen’s Aranesp and Epogen, and Novartis’ (NVS) Binocrit. In 3Q17, Aranesp and Epogen reported revenues of $516 million and $264 million, respectively.

The Health Care Select Sector SPDR Fund (XLV) invests ~11.9% of its total portfolio holdings in Johnson & Johnson.

Advertisement

More From Market Realist